Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy PLC making LIGHT work of cancer breakthrough

The company said it is now testing the Proton Source for its LIGHT system in situ in France.
Advanced Oncotherapy PLC making LIGHT work of cancer breakthrough
Proton beam therapy is expected to become a go-to cancer treatment.
A company that uses technology developed by scientists working on the large hadron collider at the CERN facility in Switzerland has moved a step closer to creating a low-cost proton beam treatment for cancer.

AIM-listed Advanced Oncotherapy PLC (LON:AVO) said it is now testing the Proton Source for its LIGHT system in situ in France. Once the testing process has been complete it will be shipped to AVO’s facility in Geneva.

LIGHT is an acronym given to the firm’s Linac Image Guided Hadron Technology.

Cheaper and smaller than the current units, which are almost prohibitively expensive, the LIGHT system has the ability to propel protons at the speed of the larger machines.

Proton beam therapy is expected to emerge as the go-to treatment for tumours as the price of the technology comes down. It uses the aforementioned protons to pinpoint tumours more precisely. This limits the damage caused by radiation to surrounding tissue and organs as well as offering patients higher disease-free survival rates. 

The piece of the kit that accelerates the protons was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the "God particle".

Of the latest developments, AVO boss Michael Sinclair said: "The team at Advanced Oncotherapy have been working hard in progressing the construction of our first LIGHT system and I am delighted that we remain on track and delivering to the timeline that we originally presented to shareholders in November 2014.

“Our LIGHT system combines some remarkable technology and it is very pleasing to see it continue to take shape - once completed we will have developed a game-changing type of proton therapy that will allow this specialist treatment to be available for cancer patients in a much more effective and affordable way."



Register here to be notified of future AVO Company articles
View full AVO profile View Profile

Advanced Oncotherapy Timeline

Related Articles

January 18 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use